1-es típusú cukorbetegség: vizsgálatok itt: Norvégia
4 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- Where
- Bergen, Loerenskog, Oslo, Stavanger
- Életkor
- 1 év to 35 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222137 · EU 2025-521797-34-00 - 3. fázisTaking peopleA Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
- Where
- Haugesund, Loerenskog, Oslo, Stavanger, Trondheim
- Életkor
- 1 év to 35 év
- People
- 300 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222332 · EU 2025-522170-36-00 - No phaseTaking peopleA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Where
- Bergen
- Életkor
- 18 év to 99 év
- People
- 24 000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05663515 - 3. fázisTaking peopleA Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
- Where
- Oslo
- Életkor
- 18 év to 65 év
- People
- 57 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04786262 · EU 2024-513929-23-00